Search Results - "Crommelin, H. A."

Infliximab therapy balances regulatory T cells, tumour necrosis factor receptor 2 (TNFR2) expression and soluble TNFR2 in sarcoidosis by Verwoerd, A., Hijdra, D., Vorselaars, A. D. M., Crommelin, H. A., van Moorsel, C. H. M., Grutters, J. C., Claessen, A. M. E.

“…Summary Sarcoidosis is a systemic granulomatous disease of unknown aetiology that most commonly affects the lungs. Although elevated levels of regulatory T…”
Get full text

D92 THE LIVING DAYLIGHTS: ILLUMINATING THE PHENOTYPING AND TREATMENT OF SARCOIDOSIS: Change Of Monocyte Subsets And Monocyte Tnf-Receptor Expression During Infliximab Therapy In Severe Sarcoidosis by Vorselaars, A D M, Hijdra, D, Meek, B, Crommelin, H A, Rijkers, G T, Claessen, A M, Deneer, V H, Van Moorsel, C H, Grutters, J C

Get full text

Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab by Crommelin, Heleen A, van der Burg, Leone M, Vorselaars, Adriane D.M, Drent, Marjolein, van Moorsel, Coline H.M, Rijkers, Ger T, Deneer, Vera H.M, Grutters, Jan C

“…Abstract Background Tumor necrosis factor-alpha (TNF-α) inhibitors are regarded as the third-line therapy in sarcoidosis, the first choice generally being…”
Get full text

Pretransplantation pharmacokinetic curves of tacrolimus in HIV-infected patients on ritonavir-containing cART: a pilot study by van Maarseveen, Erik M, Crommelin, Heleen A, Mudrikova, Tania, van den Broek, Marcel P H, van Zuilen, Arjan D

“…Ritonavir is an extremely strong inhibitor of P450 cytochrome 3A, which is the main metabolizing enzyme of tacrolimus. Subsequently, the pharmacokinetics of…”
Get full text